Abstract: Inhibitors of nitric acid synthase can be used to prevent neurotoxicity mediated through glutamate receptors. Nitric oxide synthase inhibitors can be used therapeutically in the treatment of vascular stroke and neurodegenerative disorders such as Alzheimer's disease and Huntington's disease.

Abstract: DNA molecules are taught which code for an odorant-binding protein which is synethesized solely in the lateral nasal gland. This protein, because of the broad range of odorants which it binds, can be used in many techniques for trapping odorants in either a liquid or solid medium. This protein bears some structural homology with other carriers of small lipophilic molecules from many other species; the carriers are known to transport specific lipophilic molecules.

Abstract: Primary cultures of purified olfactory neurons can be stimulated with physiological levels of ordorants. The neurons of the cultures express markers characteristic of mature olfactory neurons in vivo, such as vimentin, olfactory marker protein and neuron-specific enolase. The cultures are useful for screening for odorants and antagonists, as well as for biochemical and physiological studies of olfactory transduction. The olfactory neurons may contain at least about 95% of cells in the culture. The olfactory neurons demonstrate responsiveness in culture to IBMP, citraliva, and isovaleric acid.

Abstract: This invention is directed to continuous, non-maligant, neuronal cell lines, the cells of which: a) in the undifferentiated form are essentially free of branched process; b) stain positively for neurofilament protein and neurotransmitters; c) do not stain positively for glial fibrillary acidic protein; and d) in the presence of nerve growth factor differentiate into cells with long branched processes. Derivative cell lines of such cell lines are also contemplated. The cell lines are useful in screening methods for evaluation of chemical and biological compounds as well as for therapeutic uses.

Abstract: DNA molecules are taught which code for an odorant-binding protein which is synthesized solely in the lateral nasal gland. This protein, because of the broad range of odorants which it binds, can be used in many techniques for trapping odorants in either a liquid or solid medium. This protein bears some structural homology with other carriers of small lipophilic molecules from many other species; the carriers are known to transport specific lipophilic molecules.

Abstract: DNA molecules are taught which code for an odorant-binding protein which is synthesized solely in the lateral nasal gland. This protein, because of the broad range of odorants which it binds, can be used in many techniques for trapping odorants in either a liquid or solid medium. This protein bears some structural homology with other carriers of small lipophilic molecules from many other species; the carriers are known to transport specific lipophilic molecules.

Abstract: A process for selectively producing monoclonal antibodies which comprises selectively bringing together proliferating cells and the appropriate B-cells by means of ligand recognition of respective cell surface receptors and then fusing together the proliferating cells and B-cells thus brought together.

Abstract: Novel 8-phenylxanthines which are potent adenosine receptor antagonists.

Abstract: Novel 8-phenylxanthines which are potent adenosine receptor antagonists.

Abstract: A method for measuring the level of organic calcium antagonist drug in a body fluid comprises preparing a mixture of a radioactive calcium antagonist drug, a body fluid containing a calcium antagonist drug and a calcium antagonist receptor material, measuring the radioactivity of the radioactive calcium antagonist drug bound to said calcium antagonist receptor material and deriving the concentration of the calcium antagonist drug in the body fluid from a standard curve indicating the concentration of calcium antagonist drug versus inhibition of binding of said radioactive calcium antagonist drug to said receptor sites caused by the calcium antagonist drug in said body fluid. A kit for measuring the level of an organic calcium drug comprises a receptacle containing a radioactive calcium antagonist drug, a calcium antagonist receptor material and a standard amount of a nonradioactive calcium antagonist drug.

Abstract: Method and materials for determining levels of .beta.-adrenergic blocking drugs in body fluid, the method including the step of measuring inhibition of the binding of .beta.-adrenergic receptor binder to .beta.-adrenergic receptor material caused by .beta.-adrenergic blocker present in the body fluid.

Abstract: Method and kit for determining levels of tricyclic antidepressants in body fluid, the method including the step of measuring inhibition of the binding of radioactive muscarinic cholinergic or radioactive histamine H.sub.1 receptor binder to muscarinic cholinergic or histamine H.sub.1 receptor material caused by tricyclic antidepressant present in the body fluid.

Abstract: Method and materials for determining levels of .beta.-adrenergic blocking drugs in body fluid, the method including the step of measuring inhibition of the binding of .beta.-adrenergic receptor binder to .beta.-adrenergic receptor material caused by .beta.-adrenergic blocking drug present in the body fluid.

Abstract: Method, composition of matter and kit for determining the concentration of neuroleptic drug(s) in an animal or human patient's body fluid e.g., blood serum, blood plasma, urine, saliva, spinal fluid, etc., which comprises combining the patient's body fluid with dopamine receptor material and radioactive dopamine receptor binder and then measuring the percent inhibition of binding of the radioactive binder by the drug in the patient's fluid. The kit for performing the above method includes dopamine receptor material and radioactive dopamine receptor binder.

Abstract: A method for treating depression in humans by administering to depressed humans a composition containing an effective amount of the (-) enantiomer of trans-2-phenylcyclopropylamine or a pharmaceutically acceptable acid addition salt thereof, said composition being substantially free of (+) trans-2-phenylcyclopropylamine.